Amicus Therapeutics

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amicus Therapeutics reports robust revenue growth and eyes AT-GAA launch

Amicus Therapeutics showcased strong performance and growth prospects for Galafold and AT-GAA therapy.
The company aims for non-GAAP profitability in 2023, focusing on key strategic priorities and market expansion.
Challenges include profitability targets, regulatory approvals, and managing production costs for new therapies.
Opportunities lie in the anticipated AT-GAA launch, geographic market expansion, and continued revenue growth.

Amicus Therapeutics reports robust Q1 performance and eyes AT-GAA FDA approval

Amicus Therapeutics delivered strong Q1 results, focusing on revenue growth, regulatory milestones, and financial stability. The company's strengths lie in Galafold sales growth, positive patient outcomes with AT-GAA, and market opportunities in Pompe disease treatment. Challenges include scaling up patient numbers and transitioning manufacturing facilities, while opportunities exist in market expansion and physician engagement.

Amicus Therapeutics excels in Q2, eyes global expansion and profitability

Amicus Therapeutics demonstrates strong financial growth, focusing on expanding market presence and achieving non-GAAP profitability. The company's performance with Galafold and progress on regulatory filings position it well for future success, despite facing challenges in patient transitions and leadership changes.

Amicus Therapeutics reports robust Q3 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q3 2023, with revenue growth and profitability on track, supported by strategic investments and market expansion efforts.
The company's focus on patient-centric approaches, physician engagement, and global market penetration positions it well for future growth and success.
While facing challenges in gene therapy programs and revenue dynamics, Amicus is actively addressing these issues and leveraging opportunities in expanding markets and innovative therapies.
Overall, Amicus Therapeutics remains well-positioned in the biopharmaceutical industry, with a strong foundation for continued growth and impact in treating rare diseases.

Amicus Therapeutics reports strong Q4 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q4 2023, aiming for sustained growth and profitability in 2024 through strategic priorities and successful product launches.
The company faces challenges in forecasting seasonal trends and expanding payer coverage, yet opportunities lie in maximizing patient therapy, leveraging AI advancements, and broadening market reach.
With a focus on rare disease treatments and market penetration, Amicus is poised for growth and intervention strategies to address patient variability and drive revenue in 2024.

Amicus Therapeutics reports strong Q1 performance and growth opportunities

Amicus Therapeutics delivered strong Q1 2024 results, driven by Galafold's performance and a focus on expanding patient numbers for Pombiliti and Opfolda.
While facing challenges such as increased operating expenses and potential manufacturing issues, the company remains confident in its growth trajectory and supply capabilities.
Opportunities lie in revenue expansion, leveraging positive feedback for Pombiliti and Opfolda, and enhancing real-world evidence generation through registries.
Efforts to streamline treatment processes and establish new standards of care position Amicus for continued growth and impact in the rare disease space.

Amicus Therapeutics (FOLD) reports robust Q3 earnings and growth strategies

Amicus Therapeutics (FOLD) delivered strong financial performance in Q3 2024, driven by robust Galafold revenue and strategic focus on patient access.
While facing competitive pressures and regulatory challenges, the company aims to sustain growth through pipeline development and expense management.
Raising financial guidance and exploring accelerated approval opportunities position Amicus for continued success in the genetic medicine market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2020 Results - Earnings Call Transcript

Amicus (FOLD) posts a narrower-than-expected loss, while sales beat estimates in the second quarter of 2020.

Amicus' (FOLD) Q2 Earnings Surpass Estimates, Revenues Miss

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 23.08% and -0.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Amicus Therapeutics (FOLD) Reports Q2 Loss, Misses Revenue Estimates

Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q2 results.

Recap: Amicus Therapeutics Q2 Earnings

Galafold 2Q2020 Revenue of $62.4 Million, On-Track to Achieve 2020 Revenue Guidance of     $250M-$260M

Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates

Halozyme Therapeutics

Intercept Pharma

Novavax

Reata Pharmaceuticals

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More

CRANBURY, N.J., July  28, 2020  (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2020.

Amicus Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020

INDIANAPOLIS, July 22, 2020 /PRNewswire/ -- The National Police Association (NPA) has filed a friend of the court brief asking the U.S. District Court for the District of Oregon to rule against the self-described journalists, legal observers and photographers, who have brought suit.

National Police Association Files Amicus Brief Supporting Law Enforcement in Portland, Oregon Against Threat to Police Safety

$400M Debt Facility Provides Path to Profitability Without the Need for Any Future Dilutive Financings

Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing

Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 8.9%

Amicus Therapeutics: 2 Potential Blockbusters Make This Stock Worth Considering

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Why Is Amicus Therapeutics (FOLD) Up 10.9% Since Last Earnings Report?

Whether or not one agrees with DOJ’s call to drop its charges against former National Security Advisor Michael Flynn, there should be widespread agreement that Judge Emmet Sullivan has veered way out of line. His appointment of John Gleeson as amicus ignores two controlling higher court precedents.

Judge Sullivan Disregards Two Controlling Precedents By Appointing Amicus In Flynn Case

argenx

Ascendis Pharma

Axsome Therapeutics

Iovance Biotherapeutics

Natera

United Therapeutics

Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.

7 “Strong Buy” Healthcare Stocks to Buy Now

Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q1 2020 Results - Earnings Call Transcript

CRANBURY, N.J., May  06, 2020  (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases today announced the acceptance of several abstracts for presentation at the  American Society of Gene & Cell Therapy 23rd Annual Meeting  being held virtually on May 12 – 15. Preclinical data from its Pompe gene therapy program, which Amicus is developing with the Gene Therapy Program of the Perelman School of Medicine at the University of Pennsylvania, will be presented as an oral presentation. Preclinical data related to the CLN6 and CLN8 Batten disease programs, with our partners at Sanford Research and Nationwide Children’s Hospital, will be presented in respective posters.

UPDATE – Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting

CRANBURY, N.J., May  05, 2020  (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases today announced the acceptance of several abstracts for presentation at the  American Society of Gene & Cell Therapy 23rd Annual Meeting  being held virtually on May 12 – 15. Preclinical data from its Pompe gene therapy program, which Amicus is developing with the Gene Therapy Program of the Perelman School of Medicine at the University of Pennsylvania, will be presented as an oral presentation. Preclinical data related to the CLN6 and CLN8 Batten disease programs, with our partners at Sanford Research and Nationwide Children’s Hospital, will be presented in respective posters.

Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting

Amicus Therapeutics (FOLD) Up 1.1% Since Last Earnings Report: Can It Continue?

Alexion Pharma

Exelixis

3 Covid-19 Proof Biotech Stocks

CRANBURY, N.J., March  23, 2020  (GLOBE NEWSWIRE) --  Amicus Therapeutics  (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that the Company has proactively taken numerous measures in response to the novel coronavirus (COVID-19)  pandemic to support the rare disease community globally and to ensure the achievement of its 2020 key strategic priorities. In support of its patients, people, and programs, a COVID-19 internal Amicus task force chaired by Chairman & CEO John F. Crowley was established in early March and meets regularly via video conference to assess COVID-19 developments and their impacts on company plans and strategies.

Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees

Bicycle Therapeutics Plc - ADR

Catalyst Pharmaceuticals

Inovio Pharmaceuticals

These five biotech stocks could post life-changing gains for early-bird investors.

5 Absurdly Cheap Biotech Stocks That Could Make You Filthy Rich

Amarin Corporation Plc

CRISPR Therapeutics

Amicus Therapeutics, Amarin, and CRISPR Therapeutics are all way oversold.

With the Market Down, I'm Buying These 3 Stocks

AbbVie

Agenus

Aphria

Atreca

Bristol-Myers

Crinetics Pharmaceuticals Inc

GW Pharmaceuticals

OrganiGram Holdings Inc.

Pfizer

Arcus Biosciences

Sarepta Therapeutics

The coronavirus induced sell-off has created a number of attractive buying opportunities.

These 14 Stocks Are Stupid Cheap

Amicus (FOLD) posts a wider-than-expected loss, while sales beat estimates in the fourth quarter of 2019.

Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Surpass

Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q4 2019 Results - Earnings Call Transcript

News for Amicus Therapeutics Stock (FOLD)